Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
about
UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patientsDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsPopulation pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patientsTriclosan impairs excitation-contraction coupling and Ca2+ dynamics in striated musclePrognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patientsAbacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidationRaltegravir pharmacokinetics in neonates following maternal dosingFactors affecting drug-induced liver injury: antithyroid drugs as instances.Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Evolution of drug metabolism: hitchhiking the technology bandwagon.Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.Pharmacogenomics of human UDP-glucuronosyltransferase enzymes.Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.Genetic variants and haplotypes of the UGT1A9, 1A7 and 1A1 genes in Chinese Han.Application of chimeric mice with humanized liver for predictive ADME.Riluzole in psychiatry: a systematic review of the literature.Citrus fruit intake is associated with lower serum bilirubin concentration among women with the UGT1A1*28 polymorphismS-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysisDisparities of conjugating protective enzyme activities in the colon of patients with adenomas and carcinomas.Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis.Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based reviewUGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.Biomarkers in precision therapy in colorectal cancer.Pharmacogenetics and human genetic polymorphisms.Paracetamol metabolism and related genetic differences.Drug-induced liver injury: the role of drug metabolism and transport.Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights.Differential expression of seven conserved microRNAs in response to abiotic stress and their regulatory network in Helianthus annuus.Gene-environment interactions in esophageal cancer.Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.Expression of UDP-glucuronosyltransferase 1A, nuclear factor erythroid-E2-related factor 2 and Kelch-like ECH-associated protein 1 in colonic mucosa, adenoma and adenocarcinoma tissue.Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae.The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs.The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentiaInfluence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
P2860
Q24806179-595B21B3-5B69-4C65-B04C-9B457654636CQ26781892-45EC80A0-610A-4703-B669-03242B6E6DEFQ28272907-80E097FD-8B6E-40CF-8EBA-56845D088955Q28388309-4EE14CBD-4C65-47F7-94E4-1159A7CB43CCQ33413622-0857460B-EB80-47FB-8DB6-70E393909DF8Q33720839-A09B4272-6ACD-4368-95A1-4586374EB051Q33724160-A04BD78A-460A-4E28-9C1A-2CB5911196D3Q33861874-93E6D51E-7E20-4070-BC35-FA53F9816DB1Q34339266-D7F10C5F-C99C-4700-A527-C61216A268CCQ34339590-60270803-0D97-4648-850B-E6C793723444Q34629650-1F9044E5-7F4D-4720-9867-32BAA6A370E6Q34941200-DFA293B6-EC10-4D9A-A42E-CEC05540BAA9Q35135974-BA0CEC5D-C41D-4A55-9459-EDE77CA24EBAQ35157993-B9DB875D-1920-4E5D-B017-08B53C52FE4AQ35772582-04578EB8-AE33-4B6D-9799-B89CCFEB9DA6Q36075597-8ED87388-5952-4AB3-94E1-664DB4D1F8BAQ36761682-373DA58F-E931-49F0-9632-396B3976E224Q36983354-694D7BFB-51D3-40FE-A7D9-02B4D033E083Q37105826-67C1CB88-6382-48DE-AB9A-7F0B6F36710BQ37182236-A0814976-8E33-47CD-B0C5-D875E5AC70EDQ37203542-C6776EC9-93FE-4876-8702-505A8A217E8AQ37230200-1430B26E-F684-4DA1-BAAE-BA5A9CB5E873Q37327640-AC234F74-CE1A-45D5-818A-77CBA2E56058Q37345971-8A8DB9D0-9973-4ACD-9814-56845D0F60B6Q37345974-90126F53-8050-4351-B555-F4D8B20302E4Q37402459-AF5603D6-1DA0-4744-9A03-B48D8DD6209FQ37609130-76F1F3BC-2D90-4292-8931-FDE829C5132BQ37772183-97970A92-86A9-459E-B05C-628303C241CBQ37812385-D7DE3374-730E-4C2A-9907-2C4CB2C1BCD5Q38084215-B390A800-F297-49D9-8B65-79C97DBB7ED3Q38086603-8EAEEE7C-73BA-4C68-B933-5941418B9105Q38456730-6060C4DA-A901-4744-B921-9F65A86AF500Q38556530-BDB19B4B-CD52-425B-931F-657C2CC2E76FQ38717288-6A6A4572-643E-4526-A394-70FE48B3AED6Q40349386-2938C950-7F5B-4041-8D34-1486B24AF806Q41113863-2EAB1B88-5B20-4A39-AF83-A530CCC744FBQ41987044-68B666B2-C22B-45D6-86F9-D0B6DDE62679Q42204185-1CB811EB-86A5-4D14-BAAB-52761629CD41Q43268650-FDD641EA-D533-42B2-9FB1-F8A8521A5A2AQ45001560-8B072FFC-6391-4FD2-B5C5-051562F87452
P2860
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
@ast
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
@en
type
label
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
@ast
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
@en
prefLabel
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
@ast
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.
@en
P1433
P1476
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance
@en
P2093
John O Miners
P304
P356
10.1016/S0300-483X(02)00449-3
P407
P478
P577
2002-12-01T00:00:00Z